Whitehawk Therapeutics, Inc. (WHWK)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 10M 20M 30M Q4 '21: 14M Q1 '22: 16.2M Q2 '22: 19.6M Q3 '22: 23.9M Q4 '22: 15.2M Q1 '23: 18.8M Q2 '23: 21.5M Q3 '23: 23.3M Q4 '23: 24.4M Q1 '24: 23.8M Q2 '24: 23.8M Q3 '24: 25.1M Q4 '24: 26M Q1 '25: 27.8M Q2 '25: 21.6M Q3 '25: 14.4M Q4 '25: 7.1M Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 9M 18M 27M Q4 '21: 14M Q1 '22: 16M Q2 '22: 19.1M Q3 '22: 22.8M Q4 '22: 13.9M Q1 '23: 17.1M Q2 '23: 19.5M Q3 '23: 21.2M Q4 '23: 21.5M Q1 '24: 20.9M Q2 '24: 20.8M Q3 '24: 21.9M Q4 '24: 23M Q1 '25: 24.6M Q2 '25: 19.2M Q3 '25: 12.8M Q4 '25: 6.4M Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -100.3M Q4 '21: -111.2M Q1 '22: -120.9M Q2 '22: -135.4M Q3 '22: -63.2M Q4 '22: -62.7M Q1 '23: -65.7M Q2 '23: -66.9M Q3 '23: -69.7M Q4 '23: -71.9M Q1 '24: -74.6M Q2 '24: -70.7M Q3 '24: -66.2M Q4 '24: -67.5M Q1 '25: -63.2M Q2 '25: -102.3M Q3 '25: -108.5M Q4 '25: -114.4M Q1 '26: -122.7M Q2 '26: -86.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -86.1M Q4 '21: -110.1M Q1 '22: -118.5M Q2 '22: -135.2M Q3 '22: -62.6M Q4 '22: -60.5M Q1 '23: -61.9M Q2 '23: -61.6M Q3 '23: -63.4M Q4 '23: -65.8M Q1 '24: -68.8M Q2 '24: -65.4M Q3 '24: -61.7M Q4 '24: -63.7M Q1 '25: 27.6M Q2 '25: -10.4M Q3 '25: -15.6M Q4 '25: -20.6M Q1 '26: -115.8M Q2 '26: -79.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 1.5M 3M 4.5M Q4 '21: 0 Q1 '22: 179K Q2 '22: 520K Q3 '22: 1.1M Q4 '22: 1.3M Q1 '23: 1.7M Q2 '23: 2M Q3 '23: 2.1M Q4 '23: 2.8M Q1 '24: 2.9M Q2 '24: 3.1M Q3 '24: 3.2M Q4 '24: 3M Q1 '25: 3.1M Q2 '25: 2.4M Q3 '25: 1.6M Q4 '25: 760K Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -13.3M Q4 '21: -22.4M Q1 '22: -52.4M Q2 '22: -59.9M Q3 '22: -50.8M Q4 '22: -49.6M Q1 '23: -51.5M Q2 '23: -57.6M Q3 '23: -61.3M Q4 '23: -59.7M Q1 '24: -58M Q2 '24: -50.4M Q3 '24: -54.1M Q4 '24: -59.5M Q1 '25: -51.8M Q2 '25: -95.6M Q3 '25: -95.3M Q4 '25: -97.4M Q1 '26: -107.8M Q2 '26: -69.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q2 '19: -26.9M Q3 '19: -25.4M Q4 '19: -24.1M Q2 '22: -60.2M Q3 '22: -51.2M Q4 '22: -50.1M Q1 '23: -53.3M Q2 '23: -59.8M Q3 '23: -64.6M Q4 '23: -63.6M Q1 '24: -61.3M Q2 '24: -53.6M Q3 '24: -56.4M Q4 '24: -61.2M Q1 '25: -53.2M Q2 '25: -96.5M Q3 '25: -96M Q4 '25: -98M Q1 '26: -107.8M Q2 '26: -69.3M Q3 '19 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q3 '19: 40.6M Q1 '20: 40.6M Q2 '20: 40.9M Q3 '20: 42.1M Q2 '21: 2.5M Q3 '21: 9.5M Q1 '22: 20.9M Q2 '22: 21M Q3 '22: 21.3M Q1 '23: 26.9M Q2 '23: 26.9M Q3 '23: 26.9M Q1 '24: 27M Q2 '24: 27M Q3 '24: 27M Q1 '25: 39.9M Q2 '25: 69.1M Q3 '25: 69.2M Q1 '26: 69.2M Q2 '26: 82.9M Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -12.58 Q4 '21: -12.41 Q1 '22: -10.92 Q2 '22: -11.19 Q3 '22: -2.70 Q4 '22: -2.69 Q1 '23: -2.60 Q2 '23: -2.40 Q3 '23: -2.32 Q4 '23: -2.44 Q1 '24: -2.55 Q2 '24: -2.42 Q3 '24: -2.28 Q4 '24: -2.36 Q1 '25: 0.15 Q2 '25: -0.07 Q3 '25: 0.13 Q4 '25: -0.33 Q1 '26: -2.48 Q2 '26: -1.92 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.